Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 23, 2023 07:00 ET | Source: IN8bio, Inc

IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue

Next-generation gamma-delta T cell CAR technology targets tumors while sparing healthy tissue. Greater than 15x difference in killing between tumor cells and healthy B cells with the non-signaling...
February 21, 2023 07:00 ET | Source: IN8bio, Inc

IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference

NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today...
January 17, 2023 07:00 ET | Source: IN8bio, Inc

IN8bio to Present at the B. Riley Securities’ 3rd Annual Virtual Oncology Conference

NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today...
January 05, 2023 07:00 ET | Source: IN8bio, Inc

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

All three patients exceeded the median progression-free survival (PFS) of seven months with two ongoing responses extending beyond 1.5 years and 1.2 years progression-free, respectively, in initial...
January 03, 2023 07:00 ET | Source: IN8bio, Inc

IN8bio to Present at Biotech Showcase 2023 in San Francisco

Company to be in San Francisco January 9-11, 2023, during the 41st Annual J.P. Morgan Healthcare Conference NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage...
December 12, 2022 07:00 ET | Source: IN8bio, Inc

IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100

Results from the first cohort of patients with hematological malignancies show patients remained progression free; ongoing durations of response extend beyond 2.5 years (31.9 months)INB-100 continues...
December 08, 2022 07:00 ET | Source: IN8bio, Inc

IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

Phase 2 clinical trial initiation expected in 2023 Company to host conference call to discuss recent clinical updates, including updated data from the Phase 1 clinical trial of INB-100 being...
November 10, 2022 07:30 ET | Source: IN8bio, Inc

IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual...
November 03, 2022 09:10 ET | Source: IN8bio, Inc

IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting

Data support the potential of INB-100 to induce long-term durable responses in patients with high-risk or relapsed acute myeloid leukemia (AML).Clinical activity observed includes continuing robust...
November 01, 2022 07:30 ET | Source: IN8bio, Inc

IN8bio to Present at November Investor Conferences

NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...